Syncope — Comparative Study of the Sternal Patch System With a Conventional Holter Recorder
Citation(s)
Bigger JT Jr, Reiffel JA, Coromilas J Ambulatory electrocardiography. In: Platia E, ed. Non-Pharmacologic Management of Cardiac Arrhythmias. Philadelphia: JB Lippincott, 1986:36-61.
Clark PI, Glasser SP, Spoto E Jr Arrhythmias detected by ambulatory monitoring. Lack of correlation with symptoms of dizziness and syncope. Chest. 1980 Jun;77(6):722-5.
Gibson TC, Heitzman MR Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol. 1984 Apr 1;53(8):1013-7.
Heilbron EL Advances in modern electrocardiographic equipment for long-term ambulatory monitoring. Card Electrophysiol Rev. 2002 Sep;6(3):185-9. Review.
Jonas S, Klein I, Dimant J Importance of Holter monitoring in patients with periodic cerebral symptoms. Ann Neurol. 1977 May;1(5):470-4.
Kapoor WN, Cha R, Peterson JR, Wieand HS, Karpf M Prolonged electrocardiographic monitoring in patients with syncope. Importance of frequent or repetitive ventricular ectopy. Am J Med. 1987 Jan;82(1):20-8.
Zimetbaum P, Josephson ME Evaluation of patients with palpitations. N Engl J Med. 1998 May 7;338(19):1369-73. Review.
Comparative Study of the CarnationTM Ambulatory Monitoring Sternal ECG Patch System With a Conventional 24-Hour 7 Lead Holter Monitor Recorder
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
